What you probably already know: The women’s health care market could become even bigger than previously thought. A new report from PwC calls women’s health a $600 billion-plus opportunity by 2030, especially as underdiagnosed conditions become better identified. Other factors driving demand include the expansion of sex-specific R&D efforts and emerging AI models that could create new revenue streams. The report, “From margins to mainstream — The future of women’s health,” notes that the sector previously focused almost exclusively on reproductive care, but a broader definition that spans a woman’s entire life would create a continuous market rather than a serious of fragmented, isolated events such as pregnancy or menopause.
Why it matters: The report builds on a landmark study released earlier this year by the World Economic Forum, which predicted the women’s health economy could reach $1 trillion by 2040. PwC says expanding the definition of women’s health, particularly on conditions that disproportionately effect or are exclusive to women (think Alzheimer’s, autoimmune diseases, endometriosis, menopause and uterine fibroids, to name just a few) would fundamentally reshape the category. The investment opportunity is significant, as the core market alone is estimated at up to $440 billion across pharmaceuticals, devices and diagnostics, and providers and payers.
What it means: Women’s health still receives a tiny portion of overall investment, around 5% of total health care R&D and investment funding, but PwC projects annual growth rates of 6-8% for at least the next several years. “Importantly, these projections may understate the broader opportunity,” PwC says. “They primarily reflect currently defined categories and existing delivery models.” The growing role of digital technologies, including telehealth and data-driven tools, will give women greater control over their health and could be particularly pronounced in areas where women have historically faced stigma, such as reproductive and mental health and menopause. “Closing that gap and elevating the quality of women’s health care is not only long overdue,” the report notes. “It can represent a multibillion-dollar opportunity for investors and operators.”
What happens next: The FDA updated its clinical trial guidance last December requiring more rigorous evaluation of sex-based differences in product development, “reinforcing that biological sex must be embedded in trial design rather than as a post-hoc analysis.” The report urges pharmaceutical companies to better understand how women respond to treatments, providers to prioritize high-demand areas and employers to expand coverage for menopause care, reproductive and behavioral health and preventive diagnostics. “Health care leaders who act early can help define the future of women’s health,” it says. “In doing so, they may unlock one of the more consequential value creation opportunities in modern health care.”
